Our preliminary findings indicate that among the key enzymes of the kynurenine pathway, kynureninase (KYNU) is significantly upregulated in GBM patients, and this upregulation closely correlates with the expression of complement system-related genes. The gene discussed is KYNU; the disease is glioblastoma.